



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 8473

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.		
10/592,994	03/23/2007	514	1614	VER-209XX		
RULE						
APPLICANTS Willem Ferdinand Nieuwenhuizen, Bunnik, NETHERLANDS; Aloysius Maria Havekes, Alphen aan den Rijn, NETHERLANDS; Josephus Jan Emeis, Amsterdam, NETHERLANDS; ** CONTINUING DATA ***** This application is a 371 of PCT/NL05/00193 03/15/2005 ** FOREIGN APPLICATIONS ***** EUROPEAN PATENT OFFICE (EPO) 04075848.4 03/16/2004 EUROPEAN PATENT OFFICE (EPO) 04077088.5 07/19/2004 ** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 05/26/2007						
Foreign Priority claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 35 USC 119(a-d) conditions met <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Verified and /TIMOTHY P THOMAS/ Acknowledged Examiner's Signature		<input type="checkbox"/> Met after Allowance Initials	STATE OR COUNTRY NETHERLANDS	SHEETS DRAWINGS 2	TOTAL CLAIMS 11	INDEPENDENT CLAIMS 8
ADDRESS WEINGARTEN, SCHURGIN, GAGNEBIN & LEOVICI LLP TEN POST OFFICE SQUARE BOSTON, MA 02109 UNITED STATES						
TITLE Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome						
FILING FEE RECEIVED 2030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		